Biotek-snakken — September 2023
-
Redeye har for Calliditas Therapeutics et fair value base kursmål på: kurs 295
Calliditas Therapeutics Short: 6,02%
Blankning av Calliditas Therapeutics - Aktuell data och historik
Hur mycket blankas aktien för Calliditas Therapeutics just nu? Och hur har det förändrats? Grafer och statisitik. Aktuell data och historik.
Alla Aktier (allaaktier.se)
-
Amerikansk biotekselskab stiger efter positive forsøg med patienter med blærekræft https://www.proinvestor.com/investornyt/1053283/amerikansk-biotekselskab-stiger-efter-positive-forsog-med-patienter-med-blaerekraeft
-
-
Biosergen partnerskabsaftale med den indiske gigant Alkem Laboratories
Fik opmærksomhed i flere globale medier
Alkem Laboratories, Biosergen AB ink pact for invasive fungal diseases treatment - CNBC TV18
Business News: Get the latest Business News, Live Share & Stock Market Updates, Top News from India and across world. Read Top Business News and updates on financial, economic and banking news on CNBCTV18.
CNBCTV18 (www.cnbctv18.com)
Det svensk-danske selskab foretog en børsnotering på 231 mSEK pre-money, men er nu vurderet til knap 70 mSEK trods positive resultater og nu en aftale med big pharma.
-
STENOCARE - Significant growth in market share and patients in Denmark https://www.proinvestor.com/boards/115763
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind